Oral Povorcitinib for Extensive Nonsegmental Vitiligo Yields Positive Results in Phase 2b Trial
This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.
France General Khaled Ezzedine Kurt Brown Povorcitinib Global Program Head At Incyte European Academy Of Dermatology European Academy
Source: hcplive.com